3 years ago

EyeBiotech Secures $65 Million in Series A Funding to Develop Treatments for Sight-Threatening Eye Diseases

  • EyeBiotech, a UK-based ophthalmology biotechnology company, has raised $65 million in Series A funding led by SV Health Investors

  • The funding will be used to develop a diversified pipeline of product candidates for treating sight-threatening eye diseases

  • EyeBio was founded in 2021 by David Guyer, M.D., and Anthony P

  • Adamis, M.D., with seed funding from SV Health Investors

  • The company has assembled a strong management team with extensive experience in ophthalmology and clinical development, and a board of directors led by Kate Bingham of SV Health Investors

  • EyeBio aims to protect, restore, and improve vision in patients suffering from eye diseases.

      • ProblemHealthcare

      "Many people suffer from sight-threatening eye diseases. Current treatment options are limited and often ineffective."

      Solution

      "EyeBiotech is developing a pipeline of innovative therapies that target the root causes of these diseases, aiming to protect, restore, and improve vision for patients."

      Covered on